Literatur
-
1 Schwabe U, Paffrath D. (Hrsg). Arzneiverordnungs-Report
2009. Springer Medizin Verlag. Heidelberg; 2009
-
2 Schwabe U, Paffrath D (Hrsg).. Arzneiverordnungs-Report
2005. Springer Medizin Verlag. Heidelberg; 2005
-
3 Arzneimittelkommission
der deutschen Ärzteschaft .Empfehlungen zur
Therapie von Tumorschmerzen. 3. Auflage. Arzneiverordnung in der
Praxis (Therapieempfehlungen). Januar 2007 Band 34, Sonderheft 1
-
4
Hanks G W, Conno F, Cherny N. et al .
Morphine and alternative opioids in cancer pain:
the EAPC recommendations.
Br J Cancer.
2001;
84
587-593
-
5
Ripamonti C, Fagnoni E, Campa T. et al .
Is the use of transdermal fentanyl inappropriate
according to the WHO guidelines and the EAPC recommendations? A
study of cancer patients in Italy.
Support Care Cancer.
2006;
14
400-407
-
6 FDA .Public
Health Advisory: Important information for the safe use of fentanyl transdermal
system. 21.
Dezember 2007. http://www.fda.gov/cder/drug/advisory/fentanyl_2007.htm . (letzter Zugriff:
16. April 2007)
-
7
Medicines and Healthcare products
Regulatory Agency, Commission on Human Medicines .
Fentanyl
patches: serious and fatal overdose from dosing errors, accidental exposure,
and inappropriate use.
Drug Safety Update.
2008;
2
2-3
-
8
McMorran M.
Fentanyl transdermal patch and fatal adverse reactions.
Canadian
Adverse Reaction Newsletter.
2009;
18
1-2
-
9
Grissinger M.
Fentanyl transdermal patches: more protection needed for patients and
their families.
Pharmacy & Therapeutics.
2009;
34
343, 390
-
10
Hardwick W EJr, King W D, Palmisano P A.
Respiratory depression in a child unintentionally
exposed to transdermal fentanyl patch.
South Med J.
1997;
90
962-964
-
11
Longo M.
Fentanyl transdermal patches and accidental child exposure.
Canadian Adverse Reaction Newsletter.
2009;
19
3
-
12 Ortho-McNeil-Janssen Pharmaceuticals, Inc.:
Duragesic® (fentanyl transdermal system): Full Prescribing
Information. Revised: July 2009
-
13 Janssen L P. Important Drug Warning: Duragesic® (fentanyl transdermal
system). Healthcare Professional Letter. June 2005
-
14 Janssen-Cilag GmbH .Fachinformation „Durogesic® SMAT”. Stand: Oktober 2008
-
15
Teske J, Weller J P, Larsch K. et al .
Fatal outcome in a child after ingestion
of a transdermal fentanyl patch.
Int J Legal Med.
2007;
121
147-151
-
16
Angst M S, Clark J D.
Opioid-induced
hyperalgesia: a qualitative systematic review.
Anesthesiology.
2006;
104
570-587
-
17
Mitra S.
Opioid-induced hyperalgesia: pathophysiology and clinical implications.
J Opioid Manag.
2008;
4
123-130
Dr. med. Thomas Stammschulte
Arzneimittelkommission der deutschen Ärzteschaft
(AkdÄ)
Herbert-Lewin-Platz 1
10623
Berlin
eMail: thomas.stammschulte@akdae.de
